Key facts
- This page summarizes Samarth Kulkarni's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2024, 17:45.
Samarth Kulkarni - 29 Jan 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CRSP
- Reported as of
- 29 Jan 2024
- Net transaction value
- -$2,069,573
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2024, 17:45:05 UTC
- Prior SEC filing
- 18 Jan 2024
- Next SEC filing
- 16 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Samarth Kulkarni filed Form 4 for CRISPR Therapeutics AG (CRSP) on 31 Jan 2024.
Change
- Previous filing in this sequence was filed on 18 Jan 2024.
- Current net transaction value: -$2,069,573.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRSP
transaction
Common Shares
Options Exercise
- Transaction value
- $956,000
- Shares
- +50,000
- Change %
- +27%
- Price
- $19.12
- Shares after
- 237,377
- Date
- 29 Jan 2024
- Ownership
- Direct
CRSP
transaction
Common Shares
Sale
- Transaction value
- $2,982,803
- Shares
- -49,300
- Change %
- -21%
- Price
- $60.50
- Shares after
- 188,077
- Date
- 29 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
CRSP
transaction
Common Shares
Sale
- Transaction value
- $42,770
- Shares
- -700
- Change %
- -0.37%
- Price
- $61.10
- Shares after
- 187,377
- Date
- 29 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F3
CRSP
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 200,000
- Date
- 29 Jan 2024
- Ownership
- The Kulkarni 2023 GRAT
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRSP
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -50,000
- Change %
- -33%
- Price
- Shares after
- 100,000
- Date
- 29 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 50,000
- Exercise price
- $19.12
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.04 to $61.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.04 to $61.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F4
This performance-based stock option was granted on December 1, 2017 with respect to 150,000 Common Shares and was subject to both time- and performance-based vesting. Performance-based stock options vested as to 112,500 options on December 1, 2020 and 37,500 options on December 1, 2021, based on the Company's performance over the applicable performance period, and subject to the terms and conditions of the agreement evidencing the award and the Company's 2016 Stock Option and Incentive Plan.
Footnote F5
Not applicable.